Hong Xiao

Sichuan Agricultural University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index8.9kcitations149works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic diversity and population structure(11), DNA Repair Mechanisms(11), Plant Virus Research Studies(10), Genomics and Phylogenetic Studies(9), Acute Myeloid Leukemia Research(9)

Publications149 total

Hydroxylamine-driven O2 to H2O2 conversion via Cu(II)/Cu(I) cycling: The pivotal role of the Cu(I)(HA)4OOH complex and contributions of •OH and Cu(III) in acetaminophen degradation
Chemical Engineering Journal·2026
Hydrogen Bonding Promoting Charge Recombination over Carbon Nitride Nanodots for Fluorescent Chemosensing of Carbon Dioxide
Analytical Chemistry·2025
Whole-genome resequencing landscape of adaptive evolution in Relict gull (Larus relictus)
BMC Genomics·2025· 2 citedOpen Access
Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models
Frontiers in Pharmacology·2024· 23 citedOpen Access
Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study
Research Square (Research Square)·2024Open Access
Berberine hydrochloride delays citrus sour rot mainly by disrupting carbohydrate and energy metabolism of Geotrichum citri-aurantii spores
Pesticide Biochemistry and Physiology·2024· 7 cited
HSR24-132: Value of Early Transfusion Burden Reduction in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Journal of the National Comprehensive Cancer Network·2024
Rail Corrugation On-Board Detection Method Combined with Enhanced Cbam and Residual Network
SSRN Electronic Journal·2024Open Access
Berberine Hydrochloride Delays Citrus Sour Rot Mainly by Disrupting Carbohydrate and Energy Metabolism of Geotrichum Citri-Aurantii Spores
SSRN Electronic Journal·2024Open Access
Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept
Blood·2023· 1 cited
Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Blood·2023· 1 cited
POSTER: MDS-067 First-Line (1L) Treatment Patterns and Outcomes Among Patients With Newly Diagnosed Myelodysplastic Syndromes (MDS): A Global, Retrospective Observational Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Clinical Lymphoma Myeloma & Leukemia·2023
MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Clinical Lymphoma Myeloma & Leukemia·2023
MDS-067 First-Line (1L) Treatment Patterns and Outcomes Among Patients With Newly Diagnosed Myelodysplastic Syndromes (MDS): A Global, Retrospective Observational Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
HemaSphere·2023Open Access
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors
Journal of Medicinal Chemistry·2023· 17 citedOpen Access
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Future Oncology·2023· 3 citedOpen Access
Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-<i>b</i>]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors
Journal of Medicinal Chemistry·2023· 28 citedOpen Access
Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment
BMC Cancer·2023· 3 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Carl R. Merril(13), Mihael H. Polymeropoulos(11), D.S. Rath(7), Richard Komuniecki(7), Robert J. Hobson(4), Vera Hapiak(4), Prasanna Sivaprakasam(4), Kevin Kish(4), H.A. Lewis(4), Carol Krause(4), Catherine R. Burton(4), John E. Macor(4), Gene M. Dubowchik(4), Mark D. Adams(3), J. Craig Venter(3), Mihael H. Polymeropoulos(3), Patricia R. Komuniecki(3), Charles G. Garlisi(3), Nicolas Szapiel(3), Wendy Clarke(3)